期刊文献+

LC-ESI-MS/MS快速测定人血浆中匹伐他汀浓度 被引量:1

Rapid Determination of Pitavastatin in Plasma by LC-ESI-MS/MS
原文传递
导出
摘要 目的建立一种快速灵敏测定人体血浆中匹伐他汀浓度的高效液相色谱串联质谱检测方法。方法以AgilentC18柱(4.6mm×150mm,3.5μm)为色谱柱,流动相为甲醇-0.005mol·L^-1甲酸铵水溶液-乙腈-1%甲酸水溶液(7.5∶2.5∶70∶20);流速:0.5mL·min^-1,柱温:40℃。采用选择反应监测(SRM)对匹伐他汀(m/z422.2→290.2)和内标瑞舒伐他汀(m/z482.2→258.2)进行测定。结果匹伐他汀高(80μg·L^-1)、中(50μg·L^-1)、低(0.25μg·L^-1)3个浓度的平均回收率RSD均小于15%;线性范围为:0.1-100μg·L^-1,回归方程为Y=1.2226X-1.0561×10^-4,r=0.9960。结论该方法灵敏、准确、简单、快速,可用于匹伐他汀临床血药浓度监测和药动学研究。 OBJECTIVE To set up a rapid and sensitive LC-ESI-MS/MS method for the determination of pitavastatin in plasma. METHODS Pitavastatin was extracted with ethyl acetate-dichloromethane. The residues were analyzed with a LC-MS/MS system (Agilent Eclipse Plus C18 column, 4.6 mm×150 mm, 3.5 μm) with the mobile phase of methanol-0.005 mol·L^-1 ammonium formate aqueous solution-acetonitrile-1% formic acid(7.5∶2.5∶70∶20), with a flow rate of 0.5 mL·min^-1, temperature: 40 ℃. Selected reaction monitoring (SRM) using the precursor to production combinations of m/z 422.2→290.2 and m/z 482.2→258.2 was performed to detect pitavastatin and the internal standard, respectively. RESULTS The RSDs of average recovery of different concentration of pitavastatin(80, 50, 0.25 μg·L^-1) were less than 15%. The calibration curves for pitavastatin had good linearity over the range of 0.1-100 μg·L^-1, r=0.996 0. CONCLUSION The method provides a sensitive, accurate, precise and reliable analytical procedure for clinical monitoring of pitavastatin plasma and its phamacokinetic studies.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2010年第7期642-645,共4页 Chinese Journal of Modern Applied Pharmacy
基金 广东省自然科学研究基金资助项目(8151037001000001) 广东省医学科研基金立项(A2008559) 广东省医院药学研究基金资助项目(2008B001)
关键词 匹伐他汀 血药浓度 高效液相色谱串联质谱检测法 pitavastatin plasma concentration LC-ESI-MS/MS
  • 相关文献

参考文献5

二级参考文献44

  • 1何玉红,须媚.降血脂药 匹伐他汀(pitavastatin)[J].世界临床药物,2005,26(3):187-187. 被引量:3
  • 2何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 3张月兰,田文,张子新,曾定尹,齐国先.匹伐他汀对Klotho基因敲除杂合子小鼠血管新生的促进作用[J].中国应用生理学杂志,2006,22(2):163-167. 被引量:3
  • 4张月兰,程颖,李轶男,曾定尹,齐国先.不同剂量匹伐他汀对小鼠缺血肢血流恢复的影响[J].中国医科大学学报,2006,35(3):251-252. 被引量:2
  • 5BOLEGO C, POLI A, CIGNARELLA A, et al. Novel statins: Pharmacological and clinical results [ J ]. Cardiovasc Drugs Ther, 2002,16(3) : 251 -257.
  • 6SUZUKI M, IWASAKI H, FUJIKAWA Y, et al. Synthesis and biological evalutions of quinoline-based HMG-CoA reductase inhibitors[ J]. Bioarg Med Chem,2001,9 (10) : 2727 -2743.
  • 7SATA M, NISHIMATSU H, SLZUKI E, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia [J]. FASEB J, 2001, 15(13):2530-2532.
  • 8POURATI I, KIMMELSTIEL C, RAND W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries[ J ]. Am Heart J, 2004, 148 (5) : 21 - 23.
  • 9TOKORO T, WANG J, KITAJIMA I, et al. The novel HMG- CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO)[J]. Yakugaku Zasshi, 2004,124(3) :121 -126.
  • 10WANG JY, TOKORO T, HIGA S,et al. Anti-inflammatory effect of ptavastatin on NF-KB activated by TNF-a in hepatocellular carcinoma Ceils [ J ]. Biol Pharm Bull ,2006,29 ( 4 ) :634 - 639.

共引文献32

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部